Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.

Riess JW, Nagpal S, Das M, Neal JW, Kim JW, Wakelee HA.

J Thorac Oncol. 2013 Feb;8(2):e17-8. doi: 10.1097/JTO.0b013e31827690da. No abstract available.

2.

Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer.

Zhang YM, Li YQ, Liu ZH, Liao XL, Liang R, Lin Y, Yuan CL, Liao SN, Liang CY, Li Q, Li LQ.

Asian Pac J Cancer Prev. 2014;15(8):3447-50.

3.

Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.

Cardenal F, Arnaiz MD, Morán T, Jové J, Nadal E, Porta R, Solé JM, Brao I, Palmero R, Fuentes R, Núñez I, Caveda E, Cassinello A.

Lung Cancer. 2011 Oct;74(1):69-74. doi: 10.1016/j.lungcan.2011.01.021. Epub 2011 Feb 24.

PMID:
21353323
4.

Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature.

Singh N, Kulkarni P, Aggarwal AN, Rai Mittal B, Gupta N, Behera D, Gupta A.

Medicine (Baltimore). 2012 Jul;91(4):179-94. doi: 10.1097/MD.0b013e3182574a0b. Review.

5.

Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes.

Chang GC, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S.

Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:34-40. doi: 10.1111/j.1743-7563.2011.01400.x.

PMID:
21585706
6.

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.

Nuijten MJ, Aultman R, Carpeño Jde C, Vergnenègre A, Chouaid C, Walzer S, Siebert U.

Curr Med Res Opin. 2011 Nov;27(11):2193-201. doi: 10.1185/03007995.2011.626019. Epub 2011 Oct 4.

PMID:
21970659
7.

Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy.

Walzer S, Chouaid C, Lister J, Gultyaev D, Vergnenegre A, de Marinis F, Meng J, de Castro Carpeno J, Crott R, Kleman M, Ngoh C.

Expert Rev Anticancer Ther. 2015 Jan;15(1):121-8. doi: 10.1586/14737140.2015.961428. Epub 2014 Sep 24.

PMID:
25248391
8.

Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.

Mornex F, Peignaux K, Germain T, Wautot V, Chouaki N, Bourayou N, Tourani JM.

Lung Cancer. 2013 Apr;80(1):68-74. doi: 10.1016/j.lungcan.2012.12.007. Epub 2013 Jan 16.

PMID:
23332163
9.

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A.

Ann Oncol. 2014 May;25(5):1044-52. doi: 10.1093/annonc/mdu098. Epub 2014 Feb 27.

10.

Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.

Bischoff HG, Heigener DF, Walzer S, Nuijten M.

Lung Cancer. 2010 Aug;69 Suppl 1:S18-23. doi: 10.1016/S0169-5002(10)70134-3.

PMID:
20727458
11.

Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.

Gadgeel SM, Ruckdeschel JC, Patel BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Burger AM, Marquette L, Turrisi A.

J Thorac Oncol. 2011 May;6(5):927-33. doi: 10.1097/JTO.0b013e3182156109.

12.

Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).

Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ.

J Clin Oncol. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749. Epub 2013 Jul 8.

13.

Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.

Mir O, Boudou-Rouquette P, Giroux J, Chapron J, Alexandre J, Gibault L, Ropert S, Coriat R, Durand JP, Burgel PR, Dusser D, Goldwasser F.

Lung Cancer. 2012 Jul;77(1):104-9. doi: 10.1016/j.lungcan.2012.01.014. Epub 2012 Feb 24.

PMID:
22364783
14.

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.

Schmid-Bindert G, Gebbia V, Mayer F, Arriola E, Márquez-Medina D, Syrigos K, Biesma B, Leschinger MI, Frimodt-Moller B, Ripoche V, Myrand SP, Nguyen TS, Hozak RR, Zimmermann A, Visseren-Grul C, Schuette W.

Lung Cancer. 2013 Sep;81(3):428-34. doi: 10.1016/j.lungcan.2013.05.010. Epub 2013 Jun 20.

PMID:
23790468
15.

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG.

J Clin Oncol. 2010 Feb 1;28(4):614-9. doi: 10.1200/JCO.2009.23.6406. Epub 2009 Oct 19.

16.

High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer.

Gandhi L, Drappatz J, Ramaiya NH, Otterson GA.

J Thorac Oncol. 2013 Jan;8(1):e3-5. doi: 10.1097/JTO.0b013e3182762d20. No abstract available.

17.

Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer.

Niho S, Kubota K, Nihei K, Sekine I, Sumi M, Sekiguchi R, Funai J, Enatsu S, Ohe Y, Tamura T.

Clin Lung Cancer. 2013 Jan;14(1):62-9. doi: 10.1016/j.cllc.2012.03.007. Epub 2012 May 24.

PMID:
22633219
18.

Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.

Malhotra B, Evans T, Weiss J, Eaby B, Stonehouse-Lee S, Sherry V, Langer CJ.

Clin Lung Cancer. 2010 May;11(3):192-7. doi: 10.3816/CLC.2010.n.025.

PMID:
20439196
19.

Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer.

Li BS, Gong HY, Huang W, Yi Y, Yu JM, Wang ZT, Zhang ZC, Sun HF, Li HS, Wang LY.

Am J Clin Oncol. 2012 Apr;35(2):115-9. doi: 10.1097/COC.0b013e318209ab93.

PMID:
21555933
20.

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.

Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ.

J Thorac Oncol. 2015 Jan;10(1):134-42. doi: 10.1097/JTO.0000000000000366.

Items per page

Supplemental Content

Write to the Help Desk